Although Ads with E1b deletions and/or E1a regulated by cancer selective promoters have achieved some success in human clinical trials, the efficacy of oncolytic Ad virotherapy overall has been disappointing [22,24,30,31,32]. Here, DHTKD1 is linked to cancer.